Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834502 | 0.86 | EPHX2 (0.54) | EPHX2EPHX1GAAFAAHMAPK1 | |
| SCHEMBL75195 | 0.83 | EPHX2 (0.74) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13968192 | 0.81 | MEN1 (0.57) | EPHX2EPHX1GAAKMT2AMEN1 | |
| SCHEMBL133014 | 0.81 | EPHX1 (0.68) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL19757636 | 0.81 | EPHX1 (0.68) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13968178 | 0.80 | GRIN2D (0.57) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| Methyl Alcohol SCHEMBL23645020 | 0.79 | EPHX1 (0.66) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13834238 | 0.78 | EPHX2 (0.49) | EPHX2EPHX1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13977492 | 0.77 | EPHX2 (0.42) | EPHX2EPHX1GAAFAAH | |
| SCHEMBL16037882 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | MAVS, H1-2, ATP6AP1 | EPHX2 3599/4885EPHX1 3461/4885GAA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.